Evaluating the safety of influenza vaccine using a claims-based health system

Vaccine

Volumn 31, Issue 50, 2013, Pages 5975-5982

  McCarthy, Natalie L ^a   Gee, Julianne ^a   Lin, Nancy D ^b   Thyagarajan, Veena ^b   Pan, Yi ^a   Su, Sue ^b   Turnbull, Bruce ^b   Chan, K Arnold ^c   Weintraub, Eric ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b OPTUM   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Claims; H1N1; Influenza; Vaccine safety

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ATAXIA; BELL PALSY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CATAPLEXY; CHILD; COHORT ANALYSIS; CRANIAL NEUROPATHY; DEMYELINATING DISEASE; DRUG HYPERSENSITIVITY; ENCEPHALITIS; ENCEPHALOMYELITIS; GUILLAIN BARRE SYNDROME; HEALTH INSURANCE; HUMAN; INCIDENCE; INFANT; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MYELITIS; MYOCARDITIS; NARCOLEPSY; OUTCOME ASSESSMENT; PERICARDITIS; PERIPHERAL NEUROPATHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEASONAL INFLUENZA; SEASONAL VARIATION; SEIZURE; UNITED STATES; URTICARIA;

CLAIMS; H1N1; INFLUENZA; VACCINE SAFETY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEIZURES; YOUNG ADULT;

EID: 84887606858     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.031     Document Type: Article

References (16)

1. Sencer D.J., Millar J.D. Reflections on the 1976 swine flu vaccination program. Emerging Infectious Diseases 2006, 12(January (1)):29-33.
2. Haber P., DeStefano F., Angulo F.J., Iskander J., Shadomy S.V., Weintraub E., et al. Guillain-Barré syndrome following influenza vaccination. Journal of the American Medical Association 2004, 292(November (20)):2478-2481.
3. McMahon A.W., Iskander J., Haber P., Chang S., Woo E.J., Braun M.M., et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics 2005, 115(February (2)):453-460.
4. Zhou W., Pool V., DeStefano F., Iskander J.K., Haber P., Chen R.T., et al. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. Pharmacoepidemiology and Drug Safety 2004, 13(August (8)):505-510.
5. Jann M.W., Fidone G.S. Effect of influenza vaccine on serum anticonvulsant concentrations. Clinical Pharmacy 1986, 5(October (10)):817-820.
6. Saito H., Yanagisawa T. Acute cerebellar ataxia after influenza vaccination with recurrence and marked cerebellar atrophy. Tohoku Journal of Experimental Medicine 1989, 158(May (1)):95-103.
7. Immunization safety review: influenza vaccines and neurological complications 2003, The National Academies Press, Washington, DC.
8. Greene S.K., Rett M., Weintraub E.S., Li L., Yin R., Amato A.A., et al. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. American Journal of Epidemiology 2012, 175(June (11)):1100-1109.
9. Glanz J.M., McClure D.L., Xu S., Hambidge S.J., Lee M., Kolczak M.S., et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. Journal of Clinical Epidemiology 2006, 59(August (8)):808-818.
10. National Center for I, Respiratory Diseases CDC, Centers for Disease C, Prevention Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recommendations and Reports: Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control 2009, 58(August (RR-10)):1-8.
11. Tse A., Tseng H.F., Greene S.K., Vellozzi C., Lee G.M. Group VSDRCAIW Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012, 30(March (11)):2024-2031.
12. McAfee A.T., Chilcott K.E., Johannes C.B., Hornbuckle K., Hauser W.A., Walker A.M. The incidence of first provoked and unprovoked seizure in pediatric patients with and without psychiatric diagnoses. Epilepsia 2007, 48(June (6)):1075-1082.
13. Sejvar J.J., Kohl K.S., Gidudu J., Amato A., Bakshi N., Baxter R., et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011, 29(January (3)):599-612.
14. Yih W.K., Lee G.M., Lieu T.A., Ball R., Kulldorff M., Rett M., et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. American Journal of Epidemiology 2012, 175(June (11)):1120-1128.
15. Bohlke K., Davis R.L., DeStefano F., Marcy S.M., Braun M.M., Thompson R.S., et al. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. Journal of Allergy and Clinical Immunology 2004, 113(March (3)):536-542.
16. Greene S.K., Kulldorff M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. American Journal of Epidemiology 2010, 171(January (2)):177-188.